Inflation is rapidly eroding our purchasing power and consuming our wealth. Here is a powerful antidote for investors.
Exploring the companies and themes that make up this emerging and exciting new sector
MPV Exploration Inc. Announces Definitive Agreement for Amalgamation with Entheon Biomedical Corp and Financing
Entheon Biomedical announces a three-cornered amalgamation with MPV Exploration along with concurrent financing.
Hollister Biosciences Inc. Announces Private Placement Financing of Up to $1.5 Million
Hollister Biosciences announces a private placement for CAD$1.5 million, expected to close by July 12, 2020.
Psychedelics: A Better Way To Treat Depression
Psychedelic drugs represent a potentially enormous step forward in treating an epidemic for which there are currently no good treatment options.
MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Champignon Provides Corporate Update, Announces Name Change, Rebranding and Planned Spin Out
Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
New Wave Holdings Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.
Mydecine Innovations Inks Important Research Agreement
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Eleusis Looks For Alzheimer’s Breakthrough With Micro-Dosed LSD
Eleusis Therapeutics is a private psychedelics company that is turning a lot of heads with its research on micro-doses of LSD as a treatment for Alzheimer's.
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe
Wuhan General lines up capsule manufacturer, specializing in coffee pods.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.
Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist
Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.